Vaccination with cell immunoglobulin mucin‐1 antibodies and inactivated influenza enhances vaccine‐specific lymphocyte proliferation, interferon‐γ production and cross‐strain reactivity
Summary Influenza virus causes a contagious and potentially serious infection of the upper respiratory tract. While neutralizing antibodies are protective against infection, the problem of antigenic drift remains, requiring the constant monitoring and development of new vaccines. The magnitude of th...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental immunology 2006-07, Vol.145 (1), p.123-129 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 129 |
|---|---|
| container_issue | 1 |
| container_start_page | 123 |
| container_title | Clinical and experimental immunology |
| container_volume | 145 |
| creator | Soo Hoo, W. Jensen, E. R. Saadat, A. Nieto, D. Moss, R. B. Carlo, D. J. Moll, T. |
| description | Summary
Influenza virus causes a contagious and potentially serious infection of the upper respiratory tract. While neutralizing antibodies are protective against infection, the problem of antigenic drift remains, requiring the constant monitoring and development of new vaccines. The magnitude of this situation is underscored by the emergence of new potentially human pathogenic influenza strains, avian H5N1 being the most recent example. We present evidence that antibodies against T cell immunoglobulin mucin‐1 (TIM‐1), a recently identified immunomodulatory molecule, stimulate cellular immunity against influenza viruses and cross‐strain immune reactivity. To determine potential immunostimulatory properties of anti‐TIM‐1, mice were vaccinated with inactivated influenza virus in the presence or absence of TIM‐1‐specific monoclonal antibodies. Development of cellular immunity against both the influenza strain used for immunization and serotypically distinct virus strains was monitored 3 weeks after vaccination by determining antigen‐specific lymphocyte proliferation and cytokine production. Results show that TIM‐1 antibodies enhance antigen‐specific cellular proliferation (P |
| doi_str_mv | 10.1046/j.1365-2249.1998.00503.x-i1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68564200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68564200</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3047-cd56ced615c9b6e50c7b906418a76cdbce9ebb0841bc9973de52243f35d713283</originalsourceid><addsrcrecordid>eNqVkUFu1DAYhS1ERaeFK6BICFZNsOPEicWmaFTaSpXYAFvLcf4wHjnJYDttw4ojcBduwAF6CE6CnRnRNSvb8vf-9_Q_hF4RnBFcsLfbjFBWpnle8IxwXmcYl5hm96kmT9Dq399TtMIY85QH0TE6cW4bnoyx_Bk6JqziOavzFfr9RSqlB-n1OCR32m8SBcYkuu-nYfxqxmYyekj6KTB_fvwkiRy8bsZWgwvXNglK5fWt9BDvnZlg-C4TGDZyUAG5XYZDULodKN1plZi5321GNXtIdnY0ugO7mJ8FvQcbnmN0evgVv9tJLcGilbKjc3GStzJEsrA4az8_R0edNA5eHM5T9PnDxaf1VXrz8fJ6_f4mVRQXVarakiloGSkVbxiUWFUNx6wgtayYahsFHJoG1wVpFOcVbaEMa6QdLduK0Lymp-jNfm4I9m0C50WvXdyWHGCcnGB1yYoc4wC-24NLZAud2FndSzsLgkWsUGxFrEnEmkSsUCwVinuhSVC_PNhMTQ_to_bQWQBeHwDplDSdDbvW7pGrakZzHmOc77k7bWD-nwxifXFNCa7oX3NrxLc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68564200</pqid></control><display><type>article</type><title>Vaccination with cell immunoglobulin mucin‐1 antibodies and inactivated influenza enhances vaccine‐specific lymphocyte proliferation, interferon‐γ production and cross‐strain reactivity</title><source>PubMed Central (Open access)</source><source>MEDLINE</source><source>Oxford Academic Journals (OUP)</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Soo Hoo, W. ; Jensen, E. R. ; Saadat, A. ; Nieto, D. ; Moss, R. B. ; Carlo, D. J. ; Moll, T.</creator><creatorcontrib>Soo Hoo, W. ; Jensen, E. R. ; Saadat, A. ; Nieto, D. ; Moss, R. B. ; Carlo, D. J. ; Moll, T.</creatorcontrib><description>Summary
Influenza virus causes a contagious and potentially serious infection of the upper respiratory tract. While neutralizing antibodies are protective against infection, the problem of antigenic drift remains, requiring the constant monitoring and development of new vaccines. The magnitude of this situation is underscored by the emergence of new potentially human pathogenic influenza strains, avian H5N1 being the most recent example. We present evidence that antibodies against T cell immunoglobulin mucin‐1 (TIM‐1), a recently identified immunomodulatory molecule, stimulate cellular immunity against influenza viruses and cross‐strain immune reactivity. To determine potential immunostimulatory properties of anti‐TIM‐1, mice were vaccinated with inactivated influenza virus in the presence or absence of TIM‐1‐specific monoclonal antibodies. Development of cellular immunity against both the influenza strain used for immunization and serotypically distinct virus strains was monitored 3 weeks after vaccination by determining antigen‐specific lymphocyte proliferation and cytokine production. Results show that TIM‐1 antibodies enhance antigen‐specific cellular proliferation (P < 0·05) and interferon (IFN)‐γ production (P < 0·01). Using blocking anti‐CD4 and CD8 antibodies, it was observed that antigen‐specific cellular proliferation is CD4‐dependent and that the majority of proliferating cells are CD4+. Finally, vaccination with inactivated influenza virus with TIM‐1 antibody results in the significant (P < 0·001) induction of proliferation and IFN‐γ production upon stimulation with one of three serologically distinct strains. TIM‐1 antibodies demonstrate an adjuvant effect promoting antigen‐specific cellular proliferation and IFN‐γ production, which are important for the promotion of cell‐mediated immunity. These results are the first to suggest that TIM‐1 antibody may serve as a potent adjuvant in the development of new influenza virus vaccines.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1046/j.1365-2249.1998.00503.x-i1</identifier><identifier>PMID: 16792682</identifier><identifier>CODEN: CEXIAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>adjuvant ; Adjuvants, Immunologic - administration & dosage ; Animals ; Antibodies - administration & dosage ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - immunology ; Cell Proliferation ; Cross Reactions ; Cytokines - immunology ; Dose-Response Relationship, Drug ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Hepatitis A Virus Cellular Receptor 1 ; heterosubtypic ; IFN‐γ ; Immunization ; Immunopathology ; influenza ; Influenza Vaccines - administration & dosage ; Injections, Intraperitoneal ; Interferon-gamma - immunology ; Medical sciences ; Membrane Proteins - immunology ; Mice ; Mice, Inbred BALB C ; Orthomyxoviridae - genetics ; Orthomyxoviridae - immunology ; TIM‐1 ; Vaccines, Attenuated - administration & dosage</subject><ispartof>Clinical and experimental immunology, 2006-07, Vol.145 (1), p.123-129</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3047-cd56ced615c9b6e50c7b906418a76cdbce9ebb0841bc9973de52243f35d713283</citedby><cites>FETCH-LOGICAL-c3047-cd56ced615c9b6e50c7b906418a76cdbce9ebb0841bc9973de52243f35d713283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17863290$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16792682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soo Hoo, W.</creatorcontrib><creatorcontrib>Jensen, E. R.</creatorcontrib><creatorcontrib>Saadat, A.</creatorcontrib><creatorcontrib>Nieto, D.</creatorcontrib><creatorcontrib>Moss, R. B.</creatorcontrib><creatorcontrib>Carlo, D. J.</creatorcontrib><creatorcontrib>Moll, T.</creatorcontrib><title>Vaccination with cell immunoglobulin mucin‐1 antibodies and inactivated influenza enhances vaccine‐specific lymphocyte proliferation, interferon‐γ production and cross‐strain reactivity</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>Summary
Influenza virus causes a contagious and potentially serious infection of the upper respiratory tract. While neutralizing antibodies are protective against infection, the problem of antigenic drift remains, requiring the constant monitoring and development of new vaccines. The magnitude of this situation is underscored by the emergence of new potentially human pathogenic influenza strains, avian H5N1 being the most recent example. We present evidence that antibodies against T cell immunoglobulin mucin‐1 (TIM‐1), a recently identified immunomodulatory molecule, stimulate cellular immunity against influenza viruses and cross‐strain immune reactivity. To determine potential immunostimulatory properties of anti‐TIM‐1, mice were vaccinated with inactivated influenza virus in the presence or absence of TIM‐1‐specific monoclonal antibodies. Development of cellular immunity against both the influenza strain used for immunization and serotypically distinct virus strains was monitored 3 weeks after vaccination by determining antigen‐specific lymphocyte proliferation and cytokine production. Results show that TIM‐1 antibodies enhance antigen‐specific cellular proliferation (P < 0·05) and interferon (IFN)‐γ production (P < 0·01). Using blocking anti‐CD4 and CD8 antibodies, it was observed that antigen‐specific cellular proliferation is CD4‐dependent and that the majority of proliferating cells are CD4+. Finally, vaccination with inactivated influenza virus with TIM‐1 antibody results in the significant (P < 0·001) induction of proliferation and IFN‐γ production upon stimulation with one of three serologically distinct strains. TIM‐1 antibodies demonstrate an adjuvant effect promoting antigen‐specific cellular proliferation and IFN‐γ production, which are important for the promotion of cell‐mediated immunity. These results are the first to suggest that TIM‐1 antibody may serve as a potent adjuvant in the development of new influenza virus vaccines.</description><subject>adjuvant</subject><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Animals</subject><subject>Antibodies - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>Cell Proliferation</subject><subject>Cross Reactions</subject><subject>Cytokines - immunology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Hepatitis A Virus Cellular Receptor 1</subject><subject>heterosubtypic</subject><subject>IFN‐γ</subject><subject>Immunization</subject><subject>Immunopathology</subject><subject>influenza</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Injections, Intraperitoneal</subject><subject>Interferon-gamma - immunology</subject><subject>Medical sciences</subject><subject>Membrane Proteins - immunology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Orthomyxoviridae - genetics</subject><subject>Orthomyxoviridae - immunology</subject><subject>TIM‐1</subject><subject>Vaccines, Attenuated - administration & dosage</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkUFu1DAYhS1ERaeFK6BICFZNsOPEicWmaFTaSpXYAFvLcf4wHjnJYDttw4ojcBduwAF6CE6CnRnRNSvb8vf-9_Q_hF4RnBFcsLfbjFBWpnle8IxwXmcYl5hm96kmT9Dq399TtMIY85QH0TE6cW4bnoyx_Bk6JqziOavzFfr9RSqlB-n1OCR32m8SBcYkuu-nYfxqxmYyekj6KTB_fvwkiRy8bsZWgwvXNglK5fWt9BDvnZlg-C4TGDZyUAG5XYZDULodKN1plZi5321GNXtIdnY0ugO7mJ8FvQcbnmN0evgVv9tJLcGilbKjc3GStzJEsrA4az8_R0edNA5eHM5T9PnDxaf1VXrz8fJ6_f4mVRQXVarakiloGSkVbxiUWFUNx6wgtayYahsFHJoG1wVpFOcVbaEMa6QdLduK0Lymp-jNfm4I9m0C50WvXdyWHGCcnGB1yYoc4wC-24NLZAud2FndSzsLgkWsUGxFrEnEmkSsUCwVinuhSVC_PNhMTQ_to_bQWQBeHwDplDSdDbvW7pGrakZzHmOc77k7bWD-nwxifXFNCa7oX3NrxLc</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>Soo Hoo, W.</creator><creator>Jensen, E. R.</creator><creator>Saadat, A.</creator><creator>Nieto, D.</creator><creator>Moss, R. B.</creator><creator>Carlo, D. J.</creator><creator>Moll, T.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>Vaccination with cell immunoglobulin mucin‐1 antibodies and inactivated influenza enhances vaccine‐specific lymphocyte proliferation, interferon‐γ production and cross‐strain reactivity</title><author>Soo Hoo, W. ; Jensen, E. R. ; Saadat, A. ; Nieto, D. ; Moss, R. B. ; Carlo, D. J. ; Moll, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3047-cd56ced615c9b6e50c7b906418a76cdbce9ebb0841bc9973de52243f35d713283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>adjuvant</topic><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Animals</topic><topic>Antibodies - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>Cell Proliferation</topic><topic>Cross Reactions</topic><topic>Cytokines - immunology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Hepatitis A Virus Cellular Receptor 1</topic><topic>heterosubtypic</topic><topic>IFN‐γ</topic><topic>Immunization</topic><topic>Immunopathology</topic><topic>influenza</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Injections, Intraperitoneal</topic><topic>Interferon-gamma - immunology</topic><topic>Medical sciences</topic><topic>Membrane Proteins - immunology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Orthomyxoviridae - genetics</topic><topic>Orthomyxoviridae - immunology</topic><topic>TIM‐1</topic><topic>Vaccines, Attenuated - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soo Hoo, W.</creatorcontrib><creatorcontrib>Jensen, E. R.</creatorcontrib><creatorcontrib>Saadat, A.</creatorcontrib><creatorcontrib>Nieto, D.</creatorcontrib><creatorcontrib>Moss, R. B.</creatorcontrib><creatorcontrib>Carlo, D. J.</creatorcontrib><creatorcontrib>Moll, T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soo Hoo, W.</au><au>Jensen, E. R.</au><au>Saadat, A.</au><au>Nieto, D.</au><au>Moss, R. B.</au><au>Carlo, D. J.</au><au>Moll, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination with cell immunoglobulin mucin‐1 antibodies and inactivated influenza enhances vaccine‐specific lymphocyte proliferation, interferon‐γ production and cross‐strain reactivity</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2006-07</date><risdate>2006</risdate><volume>145</volume><issue>1</issue><spage>123</spage><epage>129</epage><pages>123-129</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><coden>CEXIAL</coden><abstract>Summary
Influenza virus causes a contagious and potentially serious infection of the upper respiratory tract. While neutralizing antibodies are protective against infection, the problem of antigenic drift remains, requiring the constant monitoring and development of new vaccines. The magnitude of this situation is underscored by the emergence of new potentially human pathogenic influenza strains, avian H5N1 being the most recent example. We present evidence that antibodies against T cell immunoglobulin mucin‐1 (TIM‐1), a recently identified immunomodulatory molecule, stimulate cellular immunity against influenza viruses and cross‐strain immune reactivity. To determine potential immunostimulatory properties of anti‐TIM‐1, mice were vaccinated with inactivated influenza virus in the presence or absence of TIM‐1‐specific monoclonal antibodies. Development of cellular immunity against both the influenza strain used for immunization and serotypically distinct virus strains was monitored 3 weeks after vaccination by determining antigen‐specific lymphocyte proliferation and cytokine production. Results show that TIM‐1 antibodies enhance antigen‐specific cellular proliferation (P < 0·05) and interferon (IFN)‐γ production (P < 0·01). Using blocking anti‐CD4 and CD8 antibodies, it was observed that antigen‐specific cellular proliferation is CD4‐dependent and that the majority of proliferating cells are CD4+. Finally, vaccination with inactivated influenza virus with TIM‐1 antibody results in the significant (P < 0·001) induction of proliferation and IFN‐γ production upon stimulation with one of three serologically distinct strains. TIM‐1 antibodies demonstrate an adjuvant effect promoting antigen‐specific cellular proliferation and IFN‐γ production, which are important for the promotion of cell‐mediated immunity. These results are the first to suggest that TIM‐1 antibody may serve as a potent adjuvant in the development of new influenza virus vaccines.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16792682</pmid><doi>10.1046/j.1365-2249.1998.00503.x-i1</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 2006-07, Vol.145 (1), p.123-129 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68564200 |
| source | PubMed Central (Open access); MEDLINE; Oxford Academic Journals (OUP); Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | adjuvant Adjuvants, Immunologic - administration & dosage Animals Antibodies - administration & dosage Biological and medical sciences CD4-Positive T-Lymphocytes - immunology Cell Proliferation Cross Reactions Cytokines - immunology Dose-Response Relationship, Drug Female Fundamental and applied biological sciences. Psychology Fundamental immunology Hepatitis A Virus Cellular Receptor 1 heterosubtypic IFN‐γ Immunization Immunopathology influenza Influenza Vaccines - administration & dosage Injections, Intraperitoneal Interferon-gamma - immunology Medical sciences Membrane Proteins - immunology Mice Mice, Inbred BALB C Orthomyxoviridae - genetics Orthomyxoviridae - immunology TIM‐1 Vaccines, Attenuated - administration & dosage |
| title | Vaccination with cell immunoglobulin mucin‐1 antibodies and inactivated influenza enhances vaccine‐specific lymphocyte proliferation, interferon‐γ production and cross‐strain reactivity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T22%3A26%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20with%20cell%20immunoglobulin%20mucin%E2%80%901%20antibodies%20and%20inactivated%20influenza%20enhances%20vaccine%E2%80%90specific%20lymphocyte%20proliferation,%20interferon%E2%80%90%CE%B3%20production%20and%20cross%E2%80%90strain%20reactivity&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=Soo%20Hoo,%20W.&rft.date=2006-07&rft.volume=145&rft.issue=1&rft.spage=123&rft.epage=129&rft.pages=123-129&rft.issn=0009-9104&rft.eissn=1365-2249&rft.coden=CEXIAL&rft_id=info:doi/10.1046/j.1365-2249.1998.00503.x-i1&rft_dat=%3Cproquest_cross%3E68564200%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68564200&rft_id=info:pmid/16792682&rfr_iscdi=true |